Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/504
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVan Den Bogaerde, J.en
dc.contributor.authorSorrentino, D.en
dc.contributor.authorFogel, S.en
dc.date.accessioned2018-06-16T20:34:58Z-
dc.date.available2018-06-16T20:34:58Z-
dc.date.issued2013en
dc.identifier.citation7, (8), 2013, p. 689-700en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/504-
dc.description.abstractSurgery has been a mainstay of therapy for Crohn's disease for a long time, essentially as a consequence of the fairly modest efficacy of traditional medications such as immunomodulators, antibiotics and 5-ASA, especially in severe cases. However, in the past decade and half, the advent of anti-TNF agents has greatly changed the medical approach to this disease and may modify its general management as well. Here, we have reviewed the current literature on incidence of surgery, timing of surgery and postoperative recurrence of Crohn's disease before and after the advent of anti-TNF agents. In addition, we have reviewed the risk of perioperative complications in patients on anti-TNF agents before surgery. The data show that the use of these medications is changing or expecting to change shortly a number of surgical aspects of Crohn's disease management. 2013 Informa UK Ltd.<br />en
dc.languageenen
dc.relation.ispartofExpert Review of Gastroenterology and Hepatologyen
dc.titleSurgery for Crohn's disease and anti-TNF agents: the changing scenarioen
dc.typeArticleen
dc.identifier.doihttp://dx.doi.org/10.1586/17474124.2013.842895en
dc.subject.keywordsanti-TNF agentsCrohn's diseaseen
dc.subject.keywordsincidence of surgeryen
dc.subject.keywordsinfliximaben
dc.subject.keywordsperioperative complicationsen
dc.subject.keywordspostoperative recurrenceen
dc.subject.keywordstiming of surgeryen
dc.subject.keywordsantibody titeren
dc.subject.keywordsclinical effectivenessen
dc.subject.keywordsCrohn disease/dt [Drug Therapy]en
dc.subject.keywordsCrohn disease/su [Surgery]en
dc.subject.keywordsdisease associationen
dc.subject.keywordsdisease controlen
dc.subject.keywordsdisease severityen
dc.subject.keywordsdose responseen
dc.subject.keywordsdrug efficacyen
dc.subject.keywordsdrug safetyen
dc.subject.keywordsdrug tolerabilityen
dc.subject.keywordshistory of medicineen
dc.subject.keywordshumanen
dc.subject.keywordsincidenceen
dc.subject.keywordsintestine surgeryen
dc.subject.keywordslaparoscopyen
dc.subject.keywordslow drug doseen
dc.subject.keywordsoutcome assessmenten
dc.subject.keywordspatient assessmenten
dc.subject.keywordspatient safetyen
dc.subject.keywordsperoperative complication/co [Complication]en
dc.subject.keywordspostoperative complication/co [Complication]en
dc.subject.keywordspremedicationen
dc.subject.keywordsrecurrent disease/co [Complication]en
dc.subject.keywordsreviewen
dc.subject.keywordsrisk assessmenten
dc.subject.keywordsrisk factoren
dc.subject.keywordssurgical infection/co [Complication]en
dc.subject.keywordsunspecified side effect/si [Side Effect]en
dc.subject.keywordsadalimumab/ct [Clinical Trial]en
dc.subject.keywordsadalimumab/dt [Drug Therapy]en
dc.subject.keywordscertolizumab/dt [Drug Therapy]en
dc.subject.keywordsinfliximab/ae [Adverse Drug Reaction]en
dc.subject.keywordsinfliximab/ct [Clinical Trial]en
dc.subject.keywordsinfliximab/cm [Drug Comparison]en
dc.subject.keywordsinfliximab/dt [Drug Therapy]en
dc.subject.keywordsmesalazine/cm [Drug Comparison]en
dc.subject.keywordsmesalazine/dt [Drug Therapy]en
dc.subject.keywordsmesalazine/po [Oral Drug Administration]en
dc.subject.keywordsmethotrexate/cm [Drug Comparison]en
dc.subject.keywordsmethotrexate/do [Drug Dose]en
dc.subject.keywordsmethotrexate/dt [Drug Therapy]en
dc.subject.keywordsmethotrexate/po [Oral Drug Administration]en
dc.subject.keywordsmonoclonal antibody/dt [Drug Therapy]en
dc.subject.keywordsplaceboen
dc.subject.keywordstumor necrosis factor alpha antibody/dt [Drug Therapy]en
dc.subject.keywordsunclassified drugen
dc.relation.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=2013708296en
dc.identifier.risid482en
dc.description.pages689-700en
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeArticle-
Appears in Sites:Sunshine Coast HHS Publications
Show simple item record

Page view(s)

92
checked on Apr 17, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.